Anavex Life Sciences Corp (AVXL)

[Schmiggins]

Nice post. I'm wondering if perhaps the "peer reviewed" thing was always waiting upon this perhaps expected change in the FDA's requirements for approval.

Wouldn't that make a lot of sense? What if our trial results had been published before this change? Wouldn't our kind of iffy results be met then with a yawn and soon forgotten? But if they are published now - after the more lenient FDA approach - they will be dramatic. And they will be noticed.

After the publication, all the other upcoming Anavex doings that Missling listed there will also take on a new significance ... and get noticed. The street - in Missling's new favorite word - will be "intrigued"!

"(1) We’re encouraged by the very recently issued FDA guidance for early Alzheimer’s disease which states that one cognitive measure alone like ADAS-Cog could be a sufficient primary endpoint for early Alzheimer’s disease...."